RPRamon de Las Peñas

Ramon de Las Peñas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ramon de Las Peñas has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • R. Rosell

    Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

    5 shared publications
  • B. Massuti

    3 shared publications
  • M. Cobo

    Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital General de Valencia, Valencia, Spain; Hospital Universitario Carlos Haya, Malaga, Spain; Autonomous University of Madrid, Madrid, Spain; Hospital General de Alicante, Alicante, Spain

    3 shared publications
  • M. Taron

    Inst Catala d’Oncologia, Badalona, Spain; Hosp Arnau de Vilanova de Valencia, Valencia, Spain; Hosp Provincial de Castellon, Castellon, Spain; Hosp Clinico Univ Lozano Blesa, Zaragoza, Spain

    3 shared publications
  • V. Alberola

    Hospital Arnau de Vilanova de Valencia, Valencia, Spain; Hospital Germans Trias i Pujol, Badalona, Spain; Hospital Provincial de Castellon, Castellon, Spain; Hospital General de Valencia, Valencia, Spain; Hospital Universitario Carlos Haya, Malaga, Spain; Autonomous University of Madrid, Madrid, Spain; Hospital General de Alicante, Alicante, Spain

    3 shared publications
  • A. Artal

    Medical Oncology, Hospital Miguel Servet

    2 shared publications

Latest Publications

  • Open Access

    SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)

    by R. de Las Peñas, A. Blasco, J. De Castro, Y. Escobar, R. García-Campelo, A. Gúrpide, R. Lopez-Lopez, M. Majem, C. A. Rodríguez, J. A. Virizuela

    Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects of chemotherapy for cancer patients. It can cause severe discomfort and affect the quality of life. In recent years, the incorporation of new drugs has increased the efficacy of antiemetic treatments in the control of emesis associated with chemotherapy. This guideline, in which we give some treatment recommendations with level of evidence and grade of recommendation, provides an update of the previously published guideline of the Spanish Society of Medical Oncology and represents our continued commitment to improving supportive care in cancer patients.


  • Open Access

    SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

    by Ramón De Las Peñas, Santiago Ponce, Fernando Henao, Carlos Camps Herrero, Enric Carcereny, Yolanda Escobar Álvarez, César A. Rodríguez, Juan Antonio Virizuela, Rafael López López


  • Lung cancer in women: Do tumors behave differently in the elderly? A prospective comparison of World07 data base

    by R. Gironés, M. Provencio, M. Majem, P. Garrido, E. Felip, N. Viñolas, A. Artal, L. Isla, E. Carcereny, C. García-Campelo, et al.

  • SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer.

    by B. Massuti, U. Jimenez, J. M. Rodriguez Paniagua, Y. W. Pun, M. Cobo, E. Carcereny Costa, R. Arrabal, J. Astudillo, I. C. Barneto, R. De Las Penas, et al.

    TPS208 Background: Postop platinum-based CT improves outcomes in completely resected NSCLC with nodal involvement, (St II-IIIA). Standard adjuvant CT is still insufficient to provide optimal survival . Improvement could be obtained through better risk selection or customized therapy. mRNA BRCA1 levels are prognostic in early NSCLC (Rosell et al 2007) and could be a predictive marker for CT activity. BRCA1 expression level could acts as a differential modulator of CT. In advanced disease p with low BRCA1 benefit from cisplatin-doublets meanwhile p with high levels BRCA1 attained longer survival when were treated with taxanes (Rosell et al 2008). Pharmacogenomic customization is feasible in adjuvant setting due to tissue availability and timelines after surgery. Previous pilot trial p with high-expression levels treated with postoperative CT singel agent taxane do not showed inferior outcomes compared to the groups treated with cisplatin-doublets (Massutí et al 2009 WLCC). Methods: Phase III prospective randomized trial of 4 cycles selected vs non-selected adjuvant CT. Eligibility criteria: NSCLC, complete R0 resection, pN1 or pN2, KI > 70, recovered from surgery, ANC > 1,500/µL, Hb > 10 g/dL, platelets > 100,000/µL, bilirrubin < 1.0 mg/dL, GOT & GPT < 1.5 x UNL, creatinine clearance > 60 mL/min, no prior RT or CT, age > 18 y, signed informed consent. Stratification factors: N1 vs N2; Histology (squamous vs non-squamous), extent of resection (lobectomy vs pneumonectomy). Central lab for measurement of mRNA BRCA1 levels and quartile distribution. Primary end-point: Disease free survival. Secondary end-points: Survival, Toxicity profiles, Recurrence pattern. Tissue and serum samples collected for Translational research. Statistical hypothesis: Randomization: 1:3 (control/experimental arms); Accrual: 432 patients; 5-year survival rate 45% control group; Absolute improvement of 20% in experimental group; 80% powered; 2-sided type I error of 5%; Anticipated loss of 10% cases. Trial design is shown in the table.

  • Phase II randomized study of preradiation treatment with temozolomide (TMZ) and bevacizumab (BEV) previous to TMZ plus radiation plus BEV versus the same treatment without BEV therapy in unresectable glioblastoma (GB): GENOM 009.

    by C. Balana, O. Gallego, J. M. Vieitez, R. De Las Penas, A. Herrero, S. Peralta, R. Luque, M. Gil, S. Villa, O. Etxaniz, et al.

    E12519 Background: Unressectable GB hardly benefits from standard treatment. Patients frequently deteriorate neurologically during radiotherapy. An effective pre-radiation treatment might improve their prognosis and allow them to complete concomitant radiotherapy and temozolomide treatment. Bevacizumab in recurrent HGG displays high objective responses. Methods: We are conducting a phase II, two arms, open label, randomized, multicentric study with 2 cycles of temozolomide before radiation therapy and concomitant temozolomide plus maintenance in patients with GB and ‘biopsy-only’ (Arm A). Bevacizumab is added to one arm during the neo-adjuvant and concomitant phase (Arm B). Ninety patients will be randomized Primary endpoints: response rate after neoadjuvant treatment (RANO criteria). Secondary endpoints: differences between arms in PFS, completion of radiotherapy, toxicity, maintenance of neurological status and overall survival We present here the previously planned results of a security analysis after the inclusion of the first 10 patients treated with bevacizumab. Results: After the inclusion of 22 patients: 2 patients were not evaluable and 10 patients were treated in each arm. Arm A: 3 adverse events: 1/10p hematological grade 4 toxicity in the neo-adjuvant phase, 2/10p lung embolism all solved with treatment. From these patients 6/10 completed neo-adjuvant and concomitant phase, 2/10 completed only neo-adjuvant phase and 2/10 progressed without completing neo-adjuvant phase. Arm B: 2 adverse events: 1 pneumonia grade 3 and 1 p with hypertensive crisis grade 2 all solved with treatment. From these patients, 7/10 p completed neo-adjuvant and concomitant treatment, 2/10 completed neo-adjuvant treatment and 1/10 progressed without completing neo-adjuvant phase Conclusions: The trial is ongoing as the security analysis was acceptable.


  • Pemetrexed as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Efficacy and correlation with molecular markers

    by A. Blasco, R. Sirera, J. Terrasa, M. Provencio, C. Guillén, I. Maestu, R. de Las Peñas, I. Bover, M. Berdiel, I. de Aguirre

    8095 Background: Pemetrexed is approved as second-line therapy in advanced NSCLC. In this study, we evaluate the efficacy and safety of pemetrexed in patients with Advanced NSCLC previously treated and we also perform a pharmacogenomic analysis to determine if biologic characteristics could be related to any clinical benefit. Methods: 195 patients with NSCLC stage IIIB (malignant pleural effusion) or IV were selected to receive pemetrexed (500 mg/m2, IV infusion) supplemented with vitamin B12, folic acid and dexamethasone prophylaxis. DNA was extracted from peripheral lymphocytes and Taqman assays for allelic discrimination were used for the following single- nucleotide polymorphism (SNP) typing: Methylene-Tetra-Hydro-Folate-Reductase (MTHFR), methionine synthase (MTR), thymidylate synthase (TS) and reduced folate carrier 1 (RFC1). Results: Median age 63 years (37–82); males: 88%; never-smokers: 9%; performance status (PS) 0: 23%; adenocarcinoma: 34%, squamous: 45%; stage IIIB: 20%, IV: 80%. The responses rates: PR 9%, SD 21%, PD 61% (9.7% pending of evaluation). Median TTP was 2.1 months (95% CI 1.9–2.3) and non statistical differences between smoking status or histology were found. Median OS was 6.7 months (m) (95% CI 5.3–8.1) and non-smokers had better OS 15.7 m (95% CI 5.3–26.1) vs 4.1 m (95% CI 3.0–5.3), p= 0.003. OS was also different by PS, PS0 9.9 m (95% CI 7.5–12.3), PS1 5.9 m (95% CI 4.5–7.2), PS2 3.1 m (95% CI 2.2–3.9) p<0.0001. Patients with adenocarcinoma presented better OS that squamous: 8.4 m (95% CI 3.5–13.7) vs 5.7m (95% CI 4.2–7.2), p= 0.22. There were no differences in clinical characteristics among the different SNP types, except TS and smoking history. No differences in response were observed according to any of the SNPs. Conclusions: More pharmacogenomic analysis will be performed to determine predictors of chemosensitivity in NSCLC, to optimize response rates and survival benefit. EGFR mutational status is being analyzed to study differences in survival for those patients with adenocarcinomas or those receiving EGFR inhibitors as third-line therapy. No significant financial relationships to disclose.


  • Cisplatin (CDDP) plus vinorelbine (NVB) as first-line treatment for advanced non-small-cell lung cancer (NSCLC): Retrospective analysis to improve the patient’s convenience on day 8 NVB administration

    by M. Provencio, R. de Las Peñas, M. Cobo, B. Massuti, A. Artal, J. M. Muñoz-Langa, R. Garcia-Gomez, A. Sanchez- Ruiz, R. Rosell

    19049 Background: Severe neutropenia observed during chemotherapy (CT) is a clinical finding leading to treatment modification and, sometimes, life-threatening events. The combination of CDDP and NVB is a reference regimen in first-line therapy for advanced NSCLC. As with other CT, a blood count must be performed prior to each administration. In order to improve treatment convenience, it would be of interest to determine a patient profile for which it would not be necessary to perform this test prior to day 8 NVB administration. Methods: Data on 180 patients (pts) included in a prospective study developed by the Spanish Lung Cancer Group have been analyzed. Multivariate logistic regression was used to determine a patient profile with low risk to develop severe neutropenia on day 8 and with no risk to present any derived haematological complication. Treatment consisted of CDDP 75 mg/m2 day 1 plus NVB 25 mg/m2, days 1, 8 every 21 days. Patient’s characteristics were: Median age 62.5 years (y) (range 39–78); males: 87.2%; smokers: 80.6%; all PS 0–1; adenocarcinoma, 48.2% / squamous, 36%; stage IIIB: 17.2%, IV: 82.8%. Results: We analyzed 750 cycles (cy). NVB was administered on day 8 on 661 cy (88.1%) and the dose reduced or canceled in 2% cy due to haematological toxicity. No risk factors have been observed on first cy. In the univariate analysis, the report of a haematological toxicity in a previous cycle was significantly associated with the finding of a new haematological toxicity. In the multivariate analysis, the best model is derived with age and haematological toxicity leading to dose modification. In a subgroup analysis, the probability to present haematological toxicity at day 8 in patients aged 70 y or less with no dose modification on the previous cy is 1.6% (CI95% [0.8%-3%]). Conclusions: The findings of this retrospective analysis could lead to consider not performing a blood count prior to day 8 NVB administration for patients aged 70 y or less who presented a good haematological tolerability profile during previous cycles following the administration of a cisplatin-based regimen for advanced NSCLC first-line treatment. A prospective trial with oral NVB and CDDP is ongoing. No significant financial relationships to disclose.


  • Translational Research In Glioblastoma Multiforme: Molecular Criteria For Patient Selection

    by Rafael Rosell, Ramon de Las Peñas, Carme Balaña, Mariacarmela Santarpia, Fernanda Salazar, Itziar de Aguirre, Noemi Reguart, Salvador Villa, Jia Wei, Jose Luis Ramirez, et al.

    In spite of the dismal outcome of glioblastoma multiforme (GBM), we are in a position to provide a ray of hope to patients and families. Methylation of MGMT in tumor occurs in approximately a third of patients and predicts meaningful response and survival to adjuvant radiotherapy plus temozolomide. Limited access to tumor tissue in some patients could be circumvented by examining MGMT methylation in circulating serum DNA, although this approach needs to be validated. Molecular signatures are also promising prognostic and predictive markers, and clinical trials should be carried out to validate their use in the selection of patients for specific targeted therapies. Gene expression by quantitative PCR of key components of these molecular signatures could pave the way for easy identification of different subgroups of patients. Translational clinical trials are warranted in order to detect the subgroups of patients resistant to radiotherapy who may derive benefit from novel therapies, including antiangiogenic...


  • 14-3-3 σ (σ) methylation (M) in pre-treatment serum DNA of cisplatin (cis)/gemcitabine (gem)-treated non-small-cell lung cancer (NSCLC)

    by J. L. Ramirez, R. Rosell, M. Taron, J. Gupta, V. Alberola, R. de Las Penas, J. M. Sanchez, T. Moran, D. Isla, S. Catot

    7042 Background: σ is a major G2/M checkpoint control gene, and disruption of its function increased DNA damage caused by irradiation and adriamycin in human cells. σ hypermethylation has been associated with loss of expression in several tumors. Methods: To determine whether σ Μ in acellular serum DNA could predict survival with gem/cis in stage IV NSCLC patients (p), we analyzed serum from blood drawn from NSCLC p before chemotherapy administration and correlated results with clinical outcome. From 1 August 2001 to 30 June 2002, 115 p were included and treated with cis 75 mg/m2, d 1, plus gem 1000 mg/m2, d 1, 8, every three weeks. Ten ml of blood were used for σ M analysis. p characteristics: 62 years (range, 31–81); male, 108 (93.9%); ECOG performance status (PS): 0, 32 (27.8%), 1, 83 (72.2%); smokers, 99 (86.1%); adenocarcinoma, 51 (44.7%), squamous cell carcinoma, 42 (36.8%), large cell carcinoma, 21 (18.4%). Results: 39 p were σ M-positive (+) and 76 M-negative (-). Median survival (MS) was 9.87 months (mos) (95% CI, 7.3–12.59) for the M- group, compared to 15.13 mos (95% CI, 9.7–20.6) for the M+ group (P=0.0047). Survival hazard ratio (HR) for σ M- status was 2.07 (95% CI, 1.24–3.45; P=0.006). MS for 22 σ Μ+ responders has not been reached, while for 29 σ M- responders, it was 11.32 mos (95% CI, 9.09–13.54) (P=0.0017). M- responders had a four times greater risk of death than M+ responders (HR = 3.95 [95% CI, 1.57–9.94]; P=0.004). Conclusions: σ M analysis in serum offers a novel and accurate method to predict survival in responders to platinum-based chemotherapy. No significant financial relationships to disclose.